Recent News

ASCO 2022: AXL Kinase Inhibitor Plus Decitabine for Prognostically Poor AML

ASCO 2022: Phase II Study of Total Oral Triplet Regimen in Older Patients With AML

ASCO 2022: Potential Triplet Regimen Under Study in FLT3-ITD–Mutated AML

ASCO 2022: Crenolanib Plus Chemotherapy in Newly Diagnosed Patients With FLT3-Mutant AML

Phase III AGILE Trial: Combining Ivosidenib With Azacitidine in IDH1-Mutated AML

Combination of Ivosidenib and Azacitidine Approved by FDA for IDH1-Mutated AML

Might Confocal Microscopy Predict Survival in Recipients of Hematopoietic Cell Transplantation?

Survival Trends in South Australia Suggest Better Therapies Needed for Older Patients With Leukemias

Validating NMT Inhibition as Novel Therapeutic Strategy for AML

AACR 2022: A New Approach to Analyzing Copy Number Abnormalities in AML

AACR 2022: Therapeutic Potential of Targeting CCRL2 in Secondary AML

AACR 2022: Could the NLRP3 Pathway Play a Role in Immune Response in Patients With AML?

FDA Brief: New CAR T-Cell Therapy Granted Fast Track Designation in AML

AACR 2022: Isoflavone Mitochondrial Inhibitor With Venetoclax Under Study in AML

Interaction of SMARCA5 and NUP98-NSD1 on Stem Cell Transformation in AML

Structural Racism and Its Impact on Survival Among Patients With AML

Is DNA Methylation of Certain Genes Prognostic of Outcomes in AML?

Searching for Optimal Front-Line Approach to Treated Secondary AML

Role of ERG Amplification in AML Oncogenesis

CD123 Overexpression in the Development of High-Risk Pediatric AML

T-Cell–Redirecting Antibody Under Study in High-Risk AML and MDS

FDA Brief: Ivosidenib for Acute Myeloid Leukemia Granted Priority Review

Using Polygenic ACS10 Score to Guide Treatment Decisions in AML

What Is the Ideal First-Line Strategy for Treated Secondary AML?

CD33: An Immunotherapeutic Target in Newly Diagnosed AML?

Two Clinical Trial Endpoints May Allow for Earlier Evaluation of Novel AML Therapies

Gilteritinib Monotherapy Plus Decitabine in Older Patients With FLT3-Mutated AML

Treatment With Ivosidenib or Enasidenib Under Study in IDH-Mutant AML

Adding Magrolimab to Chemotherapy in High-Risk Acute Myeloid Leukemia

Azacitidine Plus Ivosidenib in Patients With IDH1-Mutated AML: Global Phase III Trial

Treatment of Secondary AML and Prior Exposure to a Hypomethylating Agent

Venetoclax Plus Gilteritinib in FLT3-Mutated AML

Ivosidenib Plus Azacitidine in Older Patients With IDH1-Mutated AML

Gilteritinib Versus Chemotherapy in Asian Patients With Resistant AML: Phase III Trial

Using Triplet FLT3 Inhibitor–Based Therapy for Older Patients With AML

Impact of NPM1 and FLT3 Mutations on Prognosis in Patients With AML in Remission

Eprenetapopt Plus Azacitidine in TP53-Mutated AML After Stem Cell Transplantation